Literature DB >> 8659720

Combination of ondansetron and droperidol in the prophylaxis of postoperative nausea and vomiting.

F J Pueyo1, F Carrascosa, L Lopez, M J Iribarren, F García-Pedrajas, A Saez.   

Abstract

The aim of this study was to compare the efficacy and safety of ondansetron plus droperidol with each drug alone or placebo in the prevention of postoperative nausea and vomiting (PONV). One hundred females, aged 18-65 yr, ASA physical status I-II, undergoing general anesthesia for elective abdominal surgery were included in a prospective, double-blind, placebo-controlled, randomized study. A standardized anesthetic technique and postoperative analgesia (ketorolac plus patient-controlled analgesia [PCA] with morphine) were used in all patients. Patients were randomly assigned to receive placebo (Group 1, n = 25), droperidol 2.5 mg with induction of anesthesia and 1.25 mg 12 h later (Group 2, n = 25), ondansetron 4 mg with induction (Group 3, n = 25), and ondansetron plus droperidol at the same doses as Groups 3 and 2, respectively (Group 4, n = 25). A complete response, defined as no PONV in 48 h, occurred in 28% of patients in Group 1, 60% in Group 2 (P < 0.05 vs Group 1), 56% in Group 3 (P < 0.05 vs Group 1), and 92% in Group 4 (P < 0.01 vs Groups 1, 2, and 3). Sedation was significantly greater with droperidol (Groups 2 and 4) for 12 h postoperatively. In conclusion, the combination of ondansetron plus droperidol was more effective than each antiemetic alone or placebo in the prevention of PONV in women undergoing elective abdominal surgery.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8659720     DOI: 10.1097/00000539-199607000-00021

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  10 in total

1.  Optimising management of delirium. Placebo controlled trials of pharmacological treatments are needed.

Authors:  C J Ryan
Journal:  BMJ       Date:  2001-06-30

Review 2.  Update on the management of postoperative nausea and vomiting.

Authors:  Anthony L Kovac
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

Review 3.  When placebo controlled trials are essential and equivalence trials are inadequate.

Authors:  M R Tramèr; D J Reynolds; R A Moore; H J McQuay
Journal:  BMJ       Date:  1998-09-26

Review 4.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Prevention and treatment of postoperative nausea and vomiting.

Authors:  A L Kovac
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

6.  The Surprising Re-emergence of Droperidol.

Authors:  Kyle J Kramer
Journal:  Anesth Prog       Date:  2020-09-01

Review 7.  RETRACTED ARTICLE: Combination Antiemetic Regimens for Prevention of Postoperative Nausea and Vomiting : Focus on High-Risk Patients.

Authors:  Yoshitaka Fujii
Journal:  Clin Drug Investig       Date:  2002-09       Impact factor: 2.859

Review 8.  Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting.

Authors:  Anthony L Kovac
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.

Authors:  Stephanie Weibel; Gerta Rücker; Leopold Hj Eberhart; Nathan L Pace; Hannah M Hartl; Olivia L Jordan; Debora Mayer; Manuel Riemer; Maximilian S Schaefer; Diana Raj; Insa Backhaus; Antonia Helf; Tobias Schlesinger; Peter Kienbaum; Peter Kranke
Journal:  Cochrane Database Syst Rev       Date:  2020-10-19

10.  Ondansetron-droperidol combination vs. ondansetron or droperidol monotherapy in the prevention of postoperative nausea and vomiting.

Authors:  Paraskevi Matsota; Maria Angelidi; Aggeliki Pandazi; Konstantinos N Tzirogiannis; Georgios I Panoutsopoulos; Georgia Kostopanagiotou
Journal:  Arch Med Sci       Date:  2015-04-23       Impact factor: 3.318

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.